Introduction: Neuroendocrine tumors of the lung (BP-NETs, typical (AC) and atypical Carcinoids (ATC)) are rare tumors with heterogeneous behavior and molecular characteristics. For the intermediate proliferating BP-NETs treatment options are limited and unsatisfactory. Somatostatin analogues have not only anti-secretory effects, but also display antiproliferative features, as shown by PROMID and CLARINET trial. Nevertheless, their value in BP-NET is undefined so far.
Aim(s): To establish a preclinical model for analysis of the antiproliferative effects of the somatostatin analogue Lanreotide on BP-NETs.
Materials and methods: NCI727, NCI-720 and the well differentiated new pancreatic NT3 cell line were characterized by immunocytochemistry and FACS for the expression of somatostatin receptors (sstr). Proliferation assays were performed with an optimized treatment protocol with Lanreotide as well as combinatory treatment with the PI3Kalpha inhibitor BYL719. Functional assays and multiplexed gene expression analysis (Nanostring technologies) will be shown on the meeting.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PD Dr. Patricia Grabowski
To read results and conclusion, please login ...
Further abstracts you may be interested in